Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus (ADVAGRAF) in Kidney Transplant Recipients
Brief Summary: Aim The primary objective of this study is to compare medication adherence with medical therapy in patients receiving once-daily versus twice-daily tacrolimus regimens.

Participants 60 adult renal transplant patients randomized 1:2 into twice-daily and once-daily tacrolimus groups

Outcomes The primary outcome will be medication adherence to the once-daily and twice-daily regimens, measured in terms of implementation. Secondary outcomes will include graft and patient survival, renal function and adverse events. Follow up - 12 months


Options:
A: Inclusion Criteria:

* all eligible patients with follow-up at our outpatient clinic
* written informed consent
* sufficient German language skills to read and answer a battery of questionnaires
* \> 18 years
* minimum 6 mts post HTX

Exclusion Criteria:

* illiteracy
B: Male and female adult patients who are to receive renal transplantation may enter the study. The intention is to enroll 90 patients who have fulfilled inclusion/exclusion criteria into the study. Sixty patients will receive prolonged-release once-daily tacrolimus based therapy; the other thirty patients will receive standard twice-daily tacrolimus based therapy.

Inclusion criteria

* Male or female patients at 20-65 years of age undergoing renal transplantation
* Patients who have been informed of the potential risks and side effects of the study
* Female patients of childbearing potential must agree to maintain effective birth control during the study.
* Patients have been fully informed and have given written informed consent to participate in the study

Exclusion criteria

* Donor age greater than 65 years
* Patients receiving a perfectly matched kidney (6 matches HLA-A, B, DR)
* Patients who are recipients of multiple solid organ transplants
* Patients undergoing second or subsequent transplantation
* Patients with pre-transplant PRA \> 20%
* Patients with ABO incompatibility or positive lymphocytotoxicity
* Patients with severe, active infection
* Patients who have an abnormal liver profile such as ALT, AST, alkaline phosphatase or total bilirubin \>3 times the upper normal limit
* Patient who are HIV-positive or hepatitis C (PCR+ only) B surface antigen positive
* Patients who have been treated with an investigational drug or therapy within one month prior to entry or who will be so treated within 6 months of transplantation
* Patients with a history of malignancy within the last five years except excised squamous or basal cell carcinoma
* Patients with a history of alcohol or drug abuse or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to comply fully with the study requirements.
* Patients who require on-going dosing with a systemic immunosuppressive drugs prior to transplantation.
* Pregnant woman or breast-feeding mother during the period of this study.
* Patients who are allergy to tacrolimus, macrolide antibiotics, steroid or mycophenolate mofetil.
C: Inclusion Criteria

* Age: 18 Years to 60 Years
* Gender: both
* Patients willing and able to participate in this study
* Patients who signed the informed consent form
* Patients who can visit the center based on the study schedule in the protocol

Exclusion Criteria

* Patients who had previously received a kidney or another organ
* Patients, having positive lymphocyte cross-match
* Patients with PRA \>50%
* Patients, who underwent desensitization
* Patients, who were diagnosed with cancer in the last five years
* Patients, who themselves or their donors have positive HIV, HBsAg, or anti-HCV test results
* Patients, who were treated with other investigated drugs within 30 days from their study enrollment
* Patients, who are planning to be pregnant, or who are pregnant or breastfeeding and who are not planning to use any contraceptive method during the study period.
* Patients who were addicted to drugs/alcohol within six months of their study enrollment
* Patients, who have a mental illness that makes appropriate communication with them impossible
D: Inclusion Criteria:

* 1) age 21 or older
* 2) 5 weeks to 24 months post kidney transplant
* 3) English speaking
* 4) primarily responsible for administering own medication
* 5) owns a cell phone and comfortable receiving text messages
* 6) has access to and proficiency using internet in home

Exclusion Criteria:

* any severe, uncorrectable vision, hearing or cognitive impairments

Answer: C